Biogen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

33.37B

Market cap33.37B

Price-Earnings ratio

38.68

Price-Earnings ratio38.68

Dividend yield

—

Dividend yield—

Average volume

1.21M

Average volume1.21M

High today

$227.20

High today$227.20

Low today

$219.23

Low today$219.23

Open price

$220.62

Open price$220.62

Volume

806.64K

Volume806.64K

52 Week high

$230.49

52 Week high$230.49

52 Week low

$138.00

52 Week low$138.00

Stock Snapshot

As of today, Biogen(BIIB) shares are valued at $225.71. The company's market cap stands at 33.37B, with a P/E ratio of 38.68.

On 2026-10-09, Biogen(BIIB) stock traded between a low of $219.23 and a high of $227.20. Shares are currently priced at $225.71, which is +3.0% above the low and -0.7% below the high.

Biogen(BIIB) shares are trading with a volume of 806.64K, against a daily average of 1.21M.

During the past year, Biogen(BIIB) stock moved between $138.00 at its lowest and $230.49 at its peak.

BIIB News

TipRanks 10h

Biogen price target raised to $270 from $240 at UBS

UBS raised the firm’s price target on Biogen (BIIB) to $270 from $240 and keeps a Buy rating on the shares. The firm previewed Q3 earnings for the U.S. pharma a...

Simply Wall St 1d

Biogen, What Is Behind The Fresh Attention?

Biogen (BIIB) just released 52 week Phase 2 data from its AMETHYST trial of litifilimab in cutaneous lupus erythematosus, giving investors fresh clinical detail...

Simply Wall St 2d

How Positive Lupus Trial Data Will Impact Biogen Stock

Biogen reported 52 week Phase 2 results from the AMETHYST study of litifilimab in cutaneous lupus erythematosus, with sustained skin disease activity improvemen...

Analyst ratings

65%

of 37 ratings

Buy

64.9%

Hold

32.4%

Sell

2.7%

More BIIB News

TipRanks 2d

AI Predicted Novartis’ $30 Billion Drug Failure. Are Biogen and Takeda Next?

AI startup BioinvestGPT predicted the failure of Novartis AG’s (NVS) experimental muscular dystrophy drug months before a disappointing Phase 3 result sent the...

TipRanks 3d

Biogen Maintained at Buy as Analyst Sees Favorable Risk-Reward Ahead of Lupus Data; $256 Price Target Reaffirmed

Needham analyst Ami Fadia maintained a Buy rating on Biogen today and set a price target of $256.00. Ami Fadia has given his Buy rating due to a combination of...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.